Document Library
Click the icons below to search through Pioneer’s reports and documents.
| Filename | QALYcovid-PB.pdf |
| Filesize | 257 KB |
| Version | 1 |
| Date added | March 30, 2020 |
| Downloaded | 5538 times |
| Category | COVID, Life Sciences, Policy Briefs |
Author William S. Smith
Date: March 31, 2020
This report examines how the QALY methodology to determine drug treatment value threatens to discriminate against older adults by placing a lower value on treatments that would extend the life of or improve quality of life for older patients. This clear bias against providing access to therapies to seniors comes at a critical and especially vulnerable time for older Americans given the coronavirus disease (COVID-19). The report concludes that the QALY methodology, utilized most notably by the Institute for Clinical and Economic Review (ICER), has the potential to deny seniors’ access to high-quality, life-saving treatments.